August 29, 2019
August 29, 2019 —
Nine-month-old brains-in-a-dish and the brains of premature newborn babies generate similar electrical patterns, as captured by electroencephalogram (EEG) — the first time such brain activity has been achieved in a cell-based laboratory model.
July 25, 2024
July 25, 2024 —
An experimental cancer drug could ease cognition for individuals with Rett syndrome, a rare disorder linked to autism, according to new research from the Muotri Lab at the University of California San Diego — a discovery that could lead to therapies for patients with other neurologic conditions.
January 16, 2020
January 16, 2020 —
Two different UC San Diego research teams identified the same molecule — αvβ5 integrin — as Zika virus’ key to brain cell entry. They found ways to take advantage of the integrin to both block Zika virus from infecting cells and turn it into something good: a way to shrink…
April 6, 2023
April 6, 2023 —
After decades of working in industry and academia, biophysicists Alex Savtchenko and Elena Molokanova still have big dreams.
September 16, 2014
September 16, 2014 —
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
November 17, 2014
November 17, 2014 —
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine.
December 21, 2015
December 21, 2015 —
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the…
May 2, 2016
May 2, 2016 —
Oncternal Therapeutics, a new cancer-focused biotechnology startup, has signed a wide-ranging licensing agreement with UC San Diego to develop and commercialize antibodies and antibody-related binding agents.